The Conversation (0)
Revive Therapeutics Enters into Research Collaboration with Sanyal Biotechnology for Liver Diseases
Oct. 02, 2017 09:35AM PST
Biotech InvestingRevive Therapeutics (TSXV:RVV) has announced that it has entered into a research collaboration with Sanyal Biotechnology focused on advancing cannabinoids for treatment of liver diseases. As quoted in the press release: The collaboration will initially focus on the use of cannabidiol on a novel autoimmune hepatitis (AIH) model based on the DIAMOND™ model designed and …
Revive Therapeutics (TSXV:RVV) has announced that it has entered into a research collaboration with Sanyal Biotechnology focused on advancing cannabinoids for treatment of liver diseases.
As quoted in the press release:
The collaboration will initially focus on the use of cannabidiol on a novel autoimmune hepatitis (AIH) model based on the DIAMOND™ model designed and developed by SanyalBio specifically for Revive. The collaboration will be co-led by SanyalBio’s scientific team, including CEO Dr. Rebecca Caffrey, Dr. Prasanna Santhekadur, and Dr. Arun Sanyal. This research collaboration is expected to generate a better model of autoimmune hepatitis which will enable SanyalBio to further advance the research of cannabinoids for the treatment of AIH and other liver diseases, and the research will provide meaningful information to support future clinical research and partnering discussions for Revive.
“We look forward to working with Revive to further understand how cannabinoids’ strong anti-inflammatory properties has the potential to treat a number of liver diseases,” said Dr. Arun Sanyal, MD, Scientific Advisor for Revive and co-founder and Chief Medical Officer of Sanyal Biotechnology LLC. “SanyalBio will explore cannabidiol on a number of liver disease models based on SanyalBio’s DIAMOND™ mouse model as well as obtaining a full understanding of the mechanism of action of cannabidiol in autoimmune hepatitis (AIH), non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and fibrosis.”
“We are very pleased to collaborate with SanyalBio and Dr. Arun Sanyal, who brings an impressive track record and expertise in the preclinical and clinical development of novel therapies for liver diseases,” said Craig Leon, Chief Executive Officer of Revive. “Our focus into the research and development of novel therapies that target the CB1 and CB2 endocannabinoid receptors is becoming a significant value driver of our product pipeline and as our research progresses it will allow Revive to engage in further collaborations, business development opportunities, and potential commercial activities.”